NS...QUOTE.." If Amarin can continue to open non US markets they should be able to establish a pricing advantage in the US"....
I was thinking along the same lines...i.e....With larger volumes of sales in the U.S. and Europe and ROW, Amarin can buy large amounts of API more cheaply than generics can... and consequently beat the generics on price in the U.S. and elsewhere....This advantage in pricing can be sustained even long after U.S. patents have expired.
Once the value of Vascepa is established in the world market, its importance as an anti-inflammatory drug will become more recognized and that should boost sales volumes even more.
A BP, buying Amarin, could run a larger study than the Brave study...to demonstrate statistical significance rather than just a positive trend.
Market Data 
Markets 
AI
